Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$0.09
+0.01 (+8.14%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-52.3M · quality 71.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
10/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$200M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-15.3%
↓Gross Margin
41.3%
↓Debt/Equity
0.29
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-14.1%
FCF CAGR
—
FCF margin
-2.0%
FCF / Net income
0.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $322.9M · net income $-70.0M · FCF $-6.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $322.9M | $322.9M | $329.9M | $532.1M | $510.0M |
| Net Income | $-70.0M | $-70.0M | $-61.4M | $-24.2M | $-19.8M |
| EBITDA | $-27.1M | $-27.1M | $-11.3M | $15.7M | $-5.1M |
| EPS | — | — | -0.03 | -0.01 | -0.01 |
| Gross Margin | 41.3% | 41.3% | 46.1% | 48.0% | 47.3% |
| Operating Margin | -16.0% | -16.0% | -15.2% | -4.6% | -8.2% |
| Net Margin | -21.7% | -21.7% | -18.6% | -4.5% | -3.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.29 | 0.29 | 0.25 | 0.19 | — |
| Current Ratio | 0.83 | 0.83 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.6M | $-6.6M | $-52.3M | $-116.0M | $-54.7M |
| Returns | |||||
| ROE | -15.3% | -15.3% | -12.1% | -4.1% | — |
| Valuation | |||||
| EV/EBITDA | — | — | — | 28.19 | — |
| P/B | 0.44 | 0.44 | 0.73 | 0.83 | — |
| Growth & Yield | |||||
| Revenue Growth | -2.1% | -2.1% | -38.0% | — | — |
| EPS Growth | — | — | -154.5% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-38.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.03 → n/d
Residual
-38.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.